Survodutide tracker
Educational reference for Survodutide. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
144 h
Tmax
72 h
Category
glp1
Also known as: BI-456906
> PLACEHOLDER — pending clinical review by licensed pharmacist. Survodutide is an investigational GLP-1 / glucagon dual receptor agonist studied for obesity and liver disease. Not FDA-approved. Subcutaneous injection.
Mechanism
An investigational dual GLP-1 and glucagon receptor agonist. The combined activity is hypothesized in research to address appetite and glycemia (GLP-1) alongside increased energy expenditure and hepatic effects (glucagon).
Research summary
Investigational and not FDA-approved. It has been studied for obesity and for metabolic dysfunction-associated steatohepatitis (MASH), with phase 2 results reported and further evaluation ongoing per the literature.
Dosing in the literature
Trials have evaluated subcutaneous administration under study protocols. There is no approved regimen; this summary does not provide dosing.
Reported side effects
Gastrointestinal effects are the most commonly reported in trials, consistent with the incretin class. Given glucagon activity, metabolic parameters are monitored. The full safety profile is not yet established.
Stacking notes
As an investigational compound, combination use is confined to study settings. General incretin considerations apply.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Survodutide phase 2 trials (obesity and MASH) · peer-reviewed clinical trials (e.g. NEJM / The Lancet) (2024)search PubMed for survodutide; investigational
- GLP-1/glucagon dual agonist reviews · peer-reviewed review articles (2024)investigational; not FDA-approved
Track Survodutide in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.